¶íÂÞ˹¹ó±ö»á¼¯ÍÅ

English ¶íÂÞ˹¹ó±ö»á¼¯Íż¯ÍÅÆóÒµÓÊÏä
icon_searchclose

ʪÈóÉÕÉ˸àÒ½ÖγÁÖ¢ÈÕ¹âÆ¤Ñ×ÁÙ´²¹Û²ì

2013Äê-06ÔÂ-24ÈÕ ÆðÔ´£º¶íÂÞ˹¹ó±ö»á¼¯ÍŹú¼Ê¼¯ÍÅ

¹ãÎ÷ÎäÍþÊÐÖÐÒ½Ôº  ¬ҵÐù
 

¡¾ÌáÒª¡¿Ö÷ÕÅ  ¹Û²ìʪÈóÉÕÉ˸ࣨMEBO£©Ò½ÖγÁÖ¢ÈÕ¹âÆ¤Ñ×µÄÁÆÐ§¡£²½Öè  Æ¾¾Ý»¼ÕßËù½ÓÊܵÄÒ½Öβ½Ö裬°Ñ47Àý³ÁÖ¢ÈÕ¹âÆ¤Ñ׵ϼÕß·ÖΪ2×éÒ½ÖΡ£Ò½ÖÎ×é28Àý£¬È«³ÌͨÀýÀûÓÃMEBO±íÖΣ»¶ÔÕÕ×é19Àý£¬È«³ÌÀûÓõØÈûÃ×ËÉÈé¸à±íÖΣ¬ÁƳ̾ùΪ4 d¡£Á˾֠ 2×éÁÆÐ§ÓÐÏÔÖø²î¾à£¬Ò½ÖÎ×éÓÅÓÚ¶ÔÕÕ×é¡£½áÂÛ  MEBO¶Ô³ÁÖ¢ÈÕ¹âÆ¤Ñ×ÓµÓÐÓÅÁ¼µÄÒ½ÖÎ×÷Óá£
¡¾¹Ø¼ü´Ê¡¿MEBO£»ÈÕ¹âÆ¤Ñ×£»µØÈûÃ×ËÉ
¡¾Abstract¡¿Objective To observe the therapeutic effect of MEBO Wound Ointment £¨MEBO£©in the treatment of severe solar dermatitis. Method The  47 patients with severe solar dermatitis were randomly grouped into treatment group (28 cases) in which the topical administration of MEBO Wound Ointment was given routinely for the entire treating process and control group (19 cases) in which the Dexamethasone ointment was topically administered routinely for the whole treating process. The treating process of both groups was four days. Results The therapeutic effects of both groups had significant difference with the treatment group superior to control group. Conclusion MEBO Wound Ointment has good therapeutic effect in the treatment of severe solar dermatitis.
¡¾Key words¡¿MEBO; Dermatitis£»Dexamethasone
¡¡¡¡ÈÕ¹âÆ¤Ñ×±ðÃûɹ°ß£¬¶à²úÉúÓÚ´ºÄ©¼°ÏÄÌì¡£ÇáÕß»¼´¦Ö»Óкì°ß×ÆÍ´£¬³ÁÕߺì°ßÉ«²Ê¼ÓÉ°éÓÐË®Öס¢Ë®ðå»ò´óðå×ÆÍ´[1]¡£±¾ÎÄËùÑ¡µÄ²¡Àý£¬ÆðÔ´ÓÚ2005Äê5ÔÂÖÁ2010Äê7Ô¼äÊÕÖεÄÃÅÕﲡÀý£¬¾ùϵϺ£ÓÎÓ¾»ò²ÎÓë¾üѵ£¬Æ¤·ô¶³ö±»¾Ãɹ¶øÖµijÁ֢ɹÉË»¼Õß¡£
1.ÁÙ´²×ÊÁÏ
1.1.ͨ³£×ÊÁÏ
¡¡¡¡¶Ô´ÓǰҽÖεÄ47Àý³ÁÖ¢ÈÕ¹âÆ¤Ñײ¡Àú×ÊÁϽøÐлØÊ×ÐÔ·ÖÎö¡£Æäµ±Ñ¡È¡ÊªÈóÉÕÉ˸àÒ½ÖÎÕß28Àý£¬Î½Ö®Ò½ÖÎ×飻ÆäÓàΪ¶ÔÕÕ×飨19Àý£©¡£Ò½ÖÎ×éÄÐ15Àý£¬Å®13Àý£¬´ºÇï16Ëê~25Ë꣬¾ùÔÈÆ¤ËðÃæ»ý£¨²ÎÕÕÖйú¾Å·Ö·¨ÍÆË㣩Ϊ18%TBSA£»¶ÔÕÕ×éÄÐ10Àý£¬Å®9Àý£¬´ºÇï17Ëê~24Ë꣬¾ùÔÈÆ¤ËðÃæ»ýΪ16.5%TBSA¡£
1.2.Ò½Öβ½Öè
¡¡¡¡Á½×黼ÕßÓÃҩǰ¾ùÓڽϴóË®ðåµÄµÍλ²¿¼ôÆÆ·ÅË®£¬±£Áôð寤ÖÁµÚ3 dºóìî³ý¡£Ò½ÖÎ×é²ÎÕÕdz¢ò¶ÈÉÕÉ˵Ĵ¦Öò½Öè[2]±íÍ¿MEBO£¬ºñ¶È±¡ÓÚ1 mm£¬Ã¿6 h»»Ò©1´Î¡£¶ÔÕÕ×é¾­ÀäÉúÀíÑÎË®Çå½à´´Ãæºó£¬±íÍ¿Èý¾ÅƤÑׯ½£¨µØÈûÃ×ËÉ£©Èé¸à£¬ºñ¶È±¡ÓÚ1 mm£¬Ã¿Ìì»»Ò©3´Î£¬ÁƳ̾ùΪ4 d¡£
1.3.ÁÆÐ§³ß¶È£¨×ÔÄ⣩
¡¡¡¡È¬Óú£ººì°ßË®Ö×ÏûÍË£¬Æ¤ËðÓúºÏ£¬Í´Ö¢½â³ý£»ºÃת£ººì°ßË®Ö×ÏûÍË£¬Í´Ö¢½â³ý£¬Æ¤ËðδÍ겡ÓúºÏ£»ÎÞЧ£ºÆ¤ËðÎÞÏÔÖø¸ÄÉÆ¡£
2.Á˾Ö
¡¡¡¡Ò½ÖÎ×éȬÓú25Àý£¬ºÃת3Àý£¬È«ÊýÓÐЧ£¬ÖÎÓúÂÊΪ89.29%£»¶ÔÕÕ×éȬÓú11Àý£¬ºÃת8Àý£¬È«ÊýÓÐЧ£¬ÖÎÓúÂÊΪ57.89%¡£¾­ÓÃËĸñ±íχ2ֵУ¶Ô¼ìÑ飬Á½×éÁÆÐ§ÓÐÏÔÖø²î¾à£¬Ò½ÖÎ×éÓÅÓÚ¶ÔÕÕ×飬P<0.05¡£
3.»áÉÌ
¡¡¡¡ÖÐÒ½³ÆÈÕ¹âÆ¤Ñ×ΪÈÕɹ´¯£¬ÊÇÒò»úÌåÌ츳²»ÄÍ£¬ëíÀí²»ÃÜ£¬¹â¶¾Èȶ¾ÇÖÏ®£¬ÈȲ»±íй£¬ÓôÓÚ¼¡·ôËùÖÂ[3]¡£³ÁÖ¢Õß»¼´¦Ñª¹ÜÀ©ÕÅ£¬Ï¸°û½þÈóË®Ö×£¬±íƤΣÏÕ£¬ÕæÆ¤Å¤×ª¡£ÁÙ´²²û·¢ÀàËÆÇ³¢ò¶ÈÉÕÉË£¬¹ÊÎâÖ¾»ªµÈ[1]Ö÷ÕŲÎÕÕ¢ò¶ÈÈÈÉÕÉËÒ½ÖΡ£
¡¡¡¡MEBOÓÉ»ÆÜË¡¢»Æ°Ø¡¢»ÆÁ¬¡¢·äÀ¯¡¢ÂéÓ͵ÈÔì³É£¬ÊÇÒ½ÖÎÉÕ¡¢ÌÌ¡¢×ÆÉ˵ÄÁ¼Ò©¡£MEBO¿ÉÄÜÇåÈȽⶾ£¬½â³ý΢Ѫ¹Ü¾·ÂΣ¬¸ÄÉÆÎ¢Ñ­»·£¬±£»¤´´Ãæ¼°Éñ¾­Ä©ÉÒ£¬½â³ýÌÛÍ´£¬»¹¿ÉÄÜÎüÊÕ´´ÃæÓàÈÈ£¬ÒýÈȱí³ö£¬Ï÷¼õ½øÐÐÐÔÈÈË𣬲¢ÇÒÄܹ»ÒÖ¾ú¿¹¾ú£¬¿¹Ñ×ÏûÑ×£¬Òº»¯Åųý»µËÀ×éÖ¯£¬Íƽø×é֯ϸ°ûÔÙÉú[4]¡£¹ÊÈÕ¹âÆ¤Ñ×»¼ÕßÀûÓøÃÒ©ºó£¬¾­Âçͨ£¬ëíÀí³©£¬ÓàÈÈÇ壬¹â¶¾½â£¬ÌÛÍ´Ö¹£¬Ñ×Ö¢Ïû£¬Ë®Ö×ÍË£¬¸¯Èâìм¡Éú£¬±íƤºÏ¶ø¿µ¸´¡£
¡¡¡¡µØÈûÃ×ËÉÈé¸àËäÄÜÏûÑ׽ⶾ£¬ÏûÖ×ֹʹ£¬µ«Ã»ÓÐìÉú¼¡Ö®Ö°ÄÜ£¬¹ÊÁÆÐ§½Ï²î¡£¶Ô±¾ÁÆ·¨Ò½ÖκóδÓúºÏµÄ´´Ã棬¿É¸ÄÓÃMEBO³ÖÐøÒ½ÖΡ£
¡¡¡¡±¾×éÈ«Êý²¡ÀýµÄÈ«ÉíÖ¢×´¾ù½ÏÇᣬ²»ÐèÄÚÖΣ¬µ«Ó¦ÖöÆäά³ÖÇå½à£¬Çåµ­Òûʳ£¬ÒõÁ¹ÐÝÏ¢,¶Ô¸ÄÉÆ²¡×´´óÓÐñÔÒæ¡£
²Î¿¼Îļþ
[1]ÎâÖ¾»ª£¬·®ÒîÃ÷£¬³ÂºìÇ壬µÈ. ÏÖ´úƤ·ôÐÔ²¡Ñ§[M]. ¹ã¶«£º¹ã¶«ÈËÃñ³ö°æÉ磬2000£º682.
[2]ÐìÈÙÏ飬ФĦ£¬¼ÍÏþ·å£¬µÈ. ÉÕÉËÆ¤·ôÔÙÉúÒ½ÁƼ¼ÊõÁÙ´²ÊÖ²á[M]. ±±¾©£ºÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2003£º29£¬33~35.
[3]ÈÙÕ×ÓÑ£¬ËÎºÍÆ½£¬³Ì¸»Ç¿£¬µÈ. ÖÐҽƤ·ô¿ÆÁÙ´²ÊÖ²á[M]. ±±¾©£ºÈËÃñÎÀÉú³ö°æÉ磬1996£º253.
[4]ÐìÈÙÏ飬ФĦ£¬¼ÍÏþ·å£¬µÈ. ÉÕÉËÆ¤·ôÔÙÉúÒ½ÁƼ¼ÊõÁÙ´²ÊÖ²á[M]. ±±¾©£ºÖйúÒ½Ò©¿Æ¼¼³ö°æÉ磬2003£º27£¬52£¬54.

¡¾ÍøÕ¾µØÍ¼¡¿